루푸스 치료제 시장 : 시장 규모, 점유율, 성장, 업계 분석, 지역별 동향 및 예측(2026-2034년)

Growth Factors of lupus drugs Market

The global lupus drugs market was valued at USD 4.40 billion in 2025 and is projected to grow from USD 4.84 billion in 2026 to USD 8.95 billion by 2034, registering a CAGR of 7.99% during the forecast period. North America dominated the market with a 46.81% share in 2025, supported by strong healthcare infrastructure, high diagnosis rates, and rapid adoption of advanced biologic therapies.

Lupus is a chronic autoimmune disease that affects multiple organs, including the kidneys, skin, joints, and nervous system. Growing prevalence of systemic lupus erythematosus (SLE) and lupus nephritis, rising awareness, and improved diagnostic capabilities are driving demand for effective treatment solutions. The market is witnessing a transition from conventional immunosuppressive therapies toward targeted biologics and next-generation immunology drugs that provide better disease control and reduce long-term complications.

Leading companies including GSK plc, AstraZeneca, Aurinia Pharmaceuticals, F. Hoffmann-La Roche Ltd., and Pfizer are investing heavily in research, product development, and regulatory approvals to strengthen their market positions. Recent approvals of advanced therapies and self-administration options are further enhancing patient access and treatment convenience.

Key Market Trends

A major trend shaping the lupus drugs market is the growing adoption of targeted biologics and advanced immunology therapies. Traditional treatments such as corticosteroids and immunosuppressants often fail to provide long-term disease control and may result in significant side effects. As a result, pharmaceutical companies are focusing on therapies targeting specific immune pathways.

Biologic drugs such as BENLYSTA and SAPHNELO have demonstrated significant potential in controlling disease progression and reducing flare frequency. The introduction of subcutaneous and self-administered formulations is further improving patient compliance and expanding the market for advanced lupus therapies.

Market Drivers

Rising Prevalence of Lupus and Lupus Nephritis

The increasing number of lupus patients worldwide is one of the primary factors driving market growth. Lupus requires lifelong treatment and monitoring, creating sustained demand for therapeutics. Lupus nephritis, a severe kidney complication associated with lupus, further increases treatment intensity and healthcare spending.

Growing awareness campaigns, improved screening programs, and better access to specialist care are supporting earlier diagnosis and increasing treatment adoption globally.

Market Restraints

High Cost of Advanced Biologic Therapies

The high price of biologics and innovative therapies remains a major barrier to widespread adoption. Many healthcare systems continue to rely on conventional therapies due to budget constraints. The long-term treatment nature of lupus further increases the financial burden on patients and healthcare providers, limiting access to premium therapies in developing markets.

Market Opportunities

Expansion of Next-Generation Immunology Drugs

The growing pipeline of innovative therapies presents substantial growth opportunities. Pharmaceutical companies are developing drugs targeting specific immune mechanisms to improve disease management and reduce dependency on corticosteroids.

Regulatory approvals, pediatric indications, and at-home administration options are expanding the commercial potential of advanced therapies and opening new revenue streams for manufacturers.

Market Challenges

Disease Heterogeneity and Clinical Trial Complexity

Lupus presents differently among patients, making clinical trial design and endpoint selection challenging. Variability in disease severity and treatment response increases development risks and can delay regulatory approvals. These challenges continue to affect the pace of innovation within the market.

Segment Analysis

By Drug Class

The BLyS/BAFF inhibitors segment dominated the market in 2025 due to the strong commercial performance of BENLYSTA (belimumab). These therapies provide targeted disease management and are increasingly preferred for patients experiencing severe disease activity.

The Type I interferon receptor inhibitors segment is expected to register the fastest growth through 2034, driven by increasing adoption of advanced biologic therapies.

By Disease Indication

The Systemic Lupus Erythematosus (Non-Renal) segment accounted for the largest market share in 2025. This segment includes the largest diagnosed patient population requiring long-term treatment and disease management.

The Lupus Nephritis segment is expected to witness strong growth due to increasing diagnosis rates and the availability of specialized therapies.

By Route of Administration

The Oral segment dominated the market owing to the widespread use of antimalarials, corticosteroids, and immunosuppressants in long-term treatment.

The Subcutaneous segment is projected to grow rapidly as self-administration options improve convenience and treatment adherence.

By Age Group

The Adult segment held the largest market share in 2025, as lupus predominantly affects adults, particularly women of reproductive age. Ongoing clinical trials and regulatory approvals continue to focus heavily on this patient population.

By Type

The Generics segment dominated the market due to the extensive use of affordable therapies such as hydroxychloroquine, mycophenolate mofetil, and corticosteroids.

However, the Branded segment is expected to grow significantly due to increasing adoption of biologics and specialty drugs.

Regional Analysis

North America

North America led the global lupus drugs market with a value of USD 2.06 billion in 2025. The region benefits from strong healthcare infrastructure, advanced treatment availability, and early adoption of biologics.

The U.S. lupus drugs market is expected to reach approximately USD 2.08 billion in 2026, making it the largest country-level market globally.

Europe

Europe is expected to reach USD 1.09 billion in 2026, supported by established autoimmune disease treatment pathways and favorable reimbursement policies.

Germany and the U.K. remain major contributors to regional growth.

Asia Pacific

Asia Pacific is projected to reach USD 1.04 billion in 2026. Rising healthcare investments, improving diagnosis rates, and expanding patient awareness are driving market expansion across China, Japan, and India.

Latin America and Middle East & Africa

These regions are expected to witness moderate growth due to improving healthcare access, increasing awareness of autoimmune diseases, and gradual expansion of specialist treatment centers.

Competitive Landscape

The global lupus drugs market is highly consolidated, with major companies focusing on new product launches, clinical trials, acquisitions, and regulatory approvals to strengthen their market presence.

Key companies operating in the market include:

• GSK plc
• AstraZeneca
• Aurinia Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc.
• Sanofi
• Viatris Inc.
• Amneal Pharmaceuticals, Inc.
• AbbVie Inc.
• UCB S.A.

Recent industry developments such as FDA approvals for Gazyva in lupus nephritis, Fast Track designation for nipocalimab, and continued expansion of BENLYSTA indications are expected to intensify competition and accelerate market growth.

Conclusion

The global lupus drugs market is poised for strong growth, increasing from USD 4.40 billion in 2025 to USD 8.95 billion by 2034. Rising lupus prevalence, growing diagnosis of lupus nephritis, and increasing adoption of targeted biologics are driving market expansion. While high therapy costs and clinical trial complexities remain challenges, ongoing innovation in immunology-based therapies, regulatory approvals, and patient-friendly treatment options are expected to create significant growth opportunities throughout the forecast period.

Segmentation By Drug Class, Disease Indication, Route of Administration, Type, Age Group, Distribution Channel, and Region

By Drug Class * Antimalarials

• Corticosteroids
• Antimetabolites/Immunosuppressants
• Calcineurin Inhibitors
• BLyS/BAFF Inhibitors
• Type I Interferon Receptor Inhibitors
• Others

By Disease Indication * Systemic Lupus Erythematosus (non-renal)

• Lupus Nephritis
• Cutaneous Lupus Erythematosus
• Musculoskeletal Lupus Manifestations
• Neuropsychiatric Lupus
• Hematologic Lupus Manifestations
• Others

By Route of Administration * Oral

• Intravenous
• Subcutaneous

By Type * Branded

• Generic

By Age Group * Pediatric

• Adult
• Geriatric

By Distribution Channel * Hospital Pharmacies

• Retail / Drug Store Pharmacies
• Specialty Pharmacies
• Online Pharmacies
• Other Institutional Channels

By Region * North America (By Drug Class, Disease Indication, Route of Administration, Type, Age Group, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug Class, Disease Indication, Route of Administration, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug Class, Disease Indication, Route of Administration, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug Class, Disease Indication, Route of Administration, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug Class, Disease Indication, Route of Administration, Type, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends
• 3.5. Market Challenges

4. Key Insights

• 4.1. Prevalence of Lupus, By Key Regions/ Countries
• 4.2. New Product Launches, By Key Players
• 4.3. Overview of Regulatory Scenario, By Key Regions/ Countries
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
• 4.5. Pipeline Analysis, By Key Players

5. Global Lupus Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug Class
  • 5.1.1. Antimalarials
  • 5.1.2. Corticosteroids
  • 5.1.3. Antimetabolites/Immunosuppressants
  • 5.1.4. Calcineurin Inhibitors
  • 5.1.5. BLyS/BAFF Inhibitors
  • 5.1.6. Type I Interferon Receptor Inhibitors
  • 5.1.7. Others
• 5.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 5.2.1. Systemic Lupus Erythematosus (non-renal)
  • 5.2.2. Lupus Nephritis
  • 5.2.3. Cutaneous Lupus Erythematosus
  • 5.2.4. Musculoskeletal Lupus Manifestations
  • 5.2.5. Neuropsychiatric Lupus
  • 5.2.6. Hematologic Lupus Manifestations
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Intravenous
  • 5.3.3. Subcutaneous
• 5.4. Market Analysis, Insights and Forecast - By Type
  • 5.4.1. Branded
  • 5.4.2. Generics
• 5.5. Market Analysis, Insights and Forecast - By Age Group
  • 5.5.1. Pediatric
  • 5.5.2. Adult
  • 5.5.3. Geriatric
• 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.6.1. Hospital Pharmacies
  • 5.6.2. Retail / Drug Store Pharmacies
  • 5.6.3. Specialty Pharmacies
  • 5.6.4. Online Pharmacies
  • 5.6.5. Other Institutional Channels
• 5.7. Market Analysis, Insights and Forecast - Region
  • 5.7.1. North America
  • 5.7.2. Europe
  • 5.7.3. Asia Pacific
  • 5.7.4. Latin America
  • 5.7.5. Middle East & Africa

6. North America Lupus Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug Class
  • 6.1.1. Antimalarials
  • 6.1.2. Corticosteroids
  • 6.1.3. Antimetabolites / Immunosuppressants
  • 6.1.4. Calcineurin Inhibitors
  • 6.1.5. BLyS / BAFF Inhibitors
  • 6.1.6. Type I Interferon Receptor Inhibitors
  • 6.1.7. Others
• 6.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 6.2.1. Systemic Lupus Erythematosus (non-renal)
  • 6.2.2. Lupus Nephritis
  • 6.2.3. Cutaneous Lupus Erythematosus
  • 6.2.4. Musculoskeletal Lupus Manifestations
  • 6.2.5. Neuropsychiatric Lupus
  • 6.2.6. Hematologic Lupus Manifestations
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Intravenous
  • 6.3.3. Subcutaneous
• 6.4. Market Analysis, Insights and Forecast - By Type
  • 6.4.1. Branded
  • 6.4.2. Generics
• 6.5. Market Analysis, Insights and Forecast - By Age Group
  • 6.5.1. Pediatric
  • 6.5.2. Adult
  • 6.5.3. Geriatric
• 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.6.1. Hospital Pharmacies
  • 6.6.2. Retail / Drug Store Pharmacies
  • 6.6.3. Specialty Pharmacies
  • 6.6.4. Online Pharmacies
  • 6.6.5. Other Institutional Channels
• 6.7. Market Analysis, Insights and Forecast - By Country
  • 6.7.1. U.S.
  • 6.7.2. Canada

7. Europe Lupus Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug Class
  • 7.1.1. Antimalarials
  • 7.1.2. Corticosteroids
  • 7.1.3. Antimetabolites / Immunosuppressants
  • 7.1.4. Calcineurin Inhibitors
  • 7.1.5. BLyS / BAFF Inhibitors
  • 7.1.6. Type I Interferon Receptor Inhibitors
  • 7.1.7. Others
• 7.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 7.2.1. Systemic Lupus Erythematosus (non-renal)
  • 7.2.2. Lupus Nephritis
  • 7.2.3. Cutaneous Lupus Erythematosus
  • 7.2.4. Musculoskeletal Lupus Manifestations
  • 7.2.5. Neuropsychiatric Lupus
  • 7.2.6. Hematologic Lupus Manifestations
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Intravenous
  • 7.3.3. Subcutaneous
• 7.4. Market Analysis, Insights and Forecast - By Type
  • 7.4.1. Branded
  • 7.4.2. Generics
• 7.5. Market Analysis, Insights and Forecast - By Age Group
  • 7.5.1. Pediatric
  • 7.5.2. Adult
  • 7.5.3. Geriatric
• 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.6.1. Hospital Pharmacies
  • 7.6.2. Retail / Drug Store Pharmacies
  • 7.6.3. Specialty Pharmacies
  • 7.6.4. Online Pharmacies
  • 7.6.5. Other Institutional Channels
• 7.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.7.1. U.K.
  • 7.7.2. Germany
  • 7.7.3. France
  • 7.7.4. Italy
  • 7.7.5. Spain
  • 7.7.6. Scandinavia
  • 7.7.7. Rest of Europe

8. Asia Pacific Lupus Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug Class
  • 8.1.1. Antimalarials
  • 8.1.2. Corticosteroids
  • 8.1.3. Antimetabolites / Immunosuppressants
  • 8.1.4. Calcineurin Inhibitors
  • 8.1.5. BLyS / BAFF Inhibitors
  • 8.1.6. Type I Interferon Receptor Inhibitors
  • 8.1.7. Others
• 8.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 8.2.1. Systemic Lupus Erythematosus (non-renal)
  • 8.2.2. Lupus Nephritis
  • 8.2.3. Cutaneous Lupus Erythematosus
  • 8.2.4. Musculoskeletal Lupus Manifestations
  • 8.2.5. Neuropsychiatric Lupus
  • 8.2.6. Hematologic Lupus Manifestations
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Intravenous
  • 8.3.3. Subcutaneous
• 8.4. Market Analysis, Insights and Forecast - By Type
  • 8.4.1. Branded
  • 8.4.2. Generics
• 8.5. Market Analysis, Insights and Forecast - By Age Group
  • 8.5.1. Pediatric
  • 8.5.2. Adult
  • 8.5.3. Geriatric
• 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.6.1. Hospital Pharmacies
  • 8.6.2. Retail / Drug Store Pharmacies
  • 8.6.3. Specialty Pharmacies
  • 8.6.4. Online Pharmacies
  • 8.6.5. Other Institutional Channels
• 8.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.7.1. China
  • 8.7.2. Japan
  • 8.7.3. India
  • 8.7.4. Southeast Asia
  • 8.7.5. Australia
  • 8.7.6. Rest of Asia Pacific

9. Latin America Lupus Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug Class
  • 9.1.1. Antimalarials
  • 9.1.2. Corticosteroids
  • 9.1.3. Antimetabolites / Immunosuppressants
  • 9.1.4. Calcineurin Inhibitors
  • 9.1.5. BLyS / BAFF Inhibitors
  • 9.1.6. Type I Interferon Receptor Inhibitors
  • 9.1.7. Others
• 9.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 9.2.1. Systemic Lupus Erythematosus (non-renal)
  • 9.2.2. Lupus Nephritis
  • 9.2.3. Cutaneous Lupus Erythematosus
  • 9.2.4. Musculoskeletal Lupus Manifestations
  • 9.2.5. Neuropsychiatric Lupus
  • 9.2.6. Hematologic Lupus Manifestations
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Intravenous
  • 9.3.3. Subcutaneous
• 9.4. Market Analysis, Insights and Forecast - By Type
  • 9.4.1. Branded
  • 9.4.2. Generics
• 9.5. Market Analysis, Insights and Forecast - By Age Group
  • 9.5.1. Pediatric
  • 9.5.2. Adult
  • 9.5.3. Geriatric
• 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.6.1. Hospital Pharmacies
  • 9.6.2. Retail / Drug Store Pharmacies
  • 9.6.3. Specialty Pharmacies
  • 9.6.4. Online Pharmacies
  • 9.6.5. Other Institutional Channels
• 9.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.7.1. Brazil
  • 9.7.2. Mexico
  • 9.7.3. Rest of Latin America

10. Middle East & Africa Lupus Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug Class
  • 10.1.1. Antimalarials
  • 10.1.2. Corticosteroids
  • 10.1.3. Antimetabolites / Immunosuppressants
  • 10.1.4. Calcineurin Inhibitors
  • 10.1.5. BLyS / BAFF Inhibitors
  • 10.1.6. Type I Interferon Receptor Inhibitors
  • 10.1.7. Others
• 10.2. Market Analysis, Insights and Forecast - By Disease Indication
  • 10.2.1. Systemic Lupus Erythematosus (non-renal)
  • 10.2.2. Lupus Nephritis
  • 10.2.3. Cutaneous Lupus Erythematosus
  • 10.2.4. Musculoskeletal Lupus Manifestations
  • 10.2.5. Neuropsychiatric Lupus
  • 10.2.6. Hematologic Lupus Manifestations
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Intravenous
  • 10.3.3. Subcutaneous
• 10.4. Market Analysis, Insights and Forecast - By Type
  • 10.4.1. Branded
  • 10.4.2. Generics
• 10.5. Market Analysis, Insights and Forecast - By Age Group
  • 10.5.1. Pediatric
  • 10.5.2. Adult
  • 10.5.3. Geriatric
• 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.6.1. Hospital Pharmacies
  • 10.6.2. Retail / Drug Store Pharmacies
  • 10.6.3. Specialty Pharmacies
  • 10.6.4. Online Pharmacies
  • 10.6.5. Other Institutional Channels
• 10.7. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.7.1. GCC
  • 10.7.2. South Africa
  • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. GSK plc
  • 11.2.2. AstraZeneca
  • 11.2.3. Aurinia Pharmaceuticals Inc.
  • 11.2.4. F. Hoffmann-La Roche Ltd
  • 11.2.5. Pfizer Inc.
  • 11.2.6. Sanofi
  • 11.2.7. Viatris Inc.
  • 11.2.8. Amneal Pharmaceuticals, Inc.
  • 11.2.9. AbbVie Inc.
  • 11.2.10. UCB S.A.